/Biogen%20Inc%20logo%20on%20HQ-by%20Tada%20Images%20via%20Shutterstock.jpg)
With a market cap of $17.4 billion, Biogen Inc. (BIIB) is a global biotechnology leader focused on discovering, developing, and delivering innovative therapies for serious neurological and neurodegenerative diseases. Its portfolio includes treatments for multiple sclerosis, spinal muscular atrophy (Spinraza), Alzheimer’s disease (Aduhelm), ALS (QALSODY), and several biosimilars, with active collaborations across the biotech industry. BIIB is set to unveil its fiscal Q1 2025 earnings results before the market opens on Thursday, May 1.
Ahead of this event, analysts expect the Cambridge, Massachusetts-based company to report a profit of $3.34 per share, down nearly 9% from $3.67 per share in the year-ago quarter. However, the company has surpassed Wall Street's bottom-line estimates in the past four quarters. In Q4 2024, BIIB exceeded the consensus EPS estimate by a slight margin.